Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Domenico Rubello
Based on 5 articles published since 2009
(Why 5 articles?)
||||

Between 2009 and 2019, Domenico Rubello wrote the following 5 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Editorial Role of FDG-PET/CT in diagnosis, staging, response to treatment, and prognosis of pancreatic cancer. 2011

Grassetto, Gaia / Rubello, Domenico. · ·Am J Clin Oncol · Pubmed #21483236.

ABSTRACT: -- No abstract --

2 Article Preliminary data of the antipancreatic tumor efficacy and toxicity of long-circulating and pH-sensitive liposomes containing cisplatin. 2016

Carlesso, Fernanda N / Araújo, Raquel S / Fuscaldi, Leonardo L / Mendes Miranda, Sued E / Rubello, Domenico / Teixeira, Cláudia S / Dos Reis, Diego C / Leite, Elaine A / Silveira, Josianne N / Fernandes, Simone O A / Cassali, Geovanni D / de Oliveira, Mônica C / Colletti, Patrick M / de Barros, André L B / Cardoso, Valbert N. ·aDepartment of Clinical and Toxicological Analyses bDepartment of Pharmaceutical Products, Faculty of Pharmacy cDepartment of Pathology, Biological Science Institute, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil dDepartment of Nuclear Medicine, Santa Maria della Misericordia Hospital, Rovigo, Italy eDepartment of Nuclear Medicine, University of Southern California, Los Angeles, California, USA. ·Nucl Med Commun · Pubmed #27007915.

ABSTRACT: PURPOSE: Pancreatic cancer is the fourth most common cause of cancer-related death in the USA. This is mainly because of the chemoresistance of this type of tumor; thus, the development of novel therapeutic modalities is needed. METHODS: Long-circulating and pH-sensitive liposomes containing cisplatin (SpHL-CDDP) were administered systemically into pancreatic tumor-bearing mice for a period of 14 days. The antitumor efficacy and toxicity of this new treatment method on the basis of cisplatin-loaded liposomes was compared with the classical free-CDDP method. Tc-HYNIC-βAla-bombesin(7-14) tumor uptake and histopathologic findings were used to monitor and compare the two treatment modalities. RESULTS: The antitumor activity of SpHL-CDDP treatment was shown by (a) decrease in tumor volume, (b) development of tumor necrotic areas, and (c) decrease in Tc-HYNIC-βAla-bombesin(7-14) tumor uptake. Toxicity was evaluated by the development of inflammation and necrotic areas in the kidneys, liver, spleen, and intestine: toxic effects were greater with free-CDDP than SpHL-CDDP. CONCLUSION: SpHL-CDDP showed significant antitumor activity in pancreatic cancer-bearing mice, with lower toxicity in comparison with free-CDDP.

3 Article 68Ga DOTANOC PET/CT detects primary malignant insulinoma. 2015

Ambrosini, Valentina / Campana, Davide / Nanni, Cristina / Marzola, Maria Cristina / Rubello, Domenico / Fanti, Stefano. ·From the Departments of *Nuclear Medicine, and †Internal Medicine, Sant'Orsola-Malpighi University Hospital, Bologna; and ‡Department of Nuclear Medicine, Santa Maria della Misericordia, Rovigo, Italy. ·Clin Nucl Med · Pubmed #24830876.

ABSTRACT: Malignant insulinoma is an extremely rare pancreatic tumor variant characterized by an aggressive clinical behavior with local and distant spread. Delays in the diagnosis are common because symptoms usually precede tumor detection and may be misattributed. Aggressive surgical resection is the primary treatment option; therefore accurate tumor localization is important for appropriate management. Although somatostatin receptor imaging has a limited role in the visualization of benign insulinoma (characterized by a low expression of somatostatin receptors), it can still have a role in the detection of malignant forms.

4 Article PET/CT in the management and prognosis of pancreatic exocrine tumors. 2013

Nanni, Cristina / Fanti, Stefano / Colletti, Patrick M / Rubello, Domenico. ·Department of Nuclear Medicine, Azienda Ospedaliero Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy. ·Clin Nucl Med · Pubmed #23242042.

ABSTRACT: -- No abstract --

5 Article DCE-MRI using small-molecular and albumin-binding contrast agents in experimental carcinomas with different stromal content. 2011

Farace, Paolo / Merigo, Flavia / Fiorini, Silvia / Nicolato, Elena / Tambalo, Stefano / Daducci, Alessandro / Degrassi, Anna / Sbarbati, Andrea / Rubello, Domenico / Marzola, Pasquina. ·Department of Morphological-Biomedical Sciences, Section of Anatomy and Histology, University of Verona, Verona, Italy. ·Eur J Radiol · Pubmed #19443159.

ABSTRACT: OBJECTIVES: To compare DCE-MRI experiments performed using a standard small-molecular (Gd-DTPA) and an albumin-binding (MS-325) contrast agent in two carcinoma models with different stromal content. MATERIALS AND METHODS: DU-145 or BXPC-3 cancer cells were subcutaneously injected into nude mice. DCE-MRI was performed by a bolus injection of Gd-DTPA or MS-325 about 2 weeks after inoculation. For quantitative analysis a volume of interest was manually drawn over each tumor. To address the heterogeneous enhancement, each tumor volume was then divided into the 20% most-enhancing and the remaining 80% least-enhancing fractions. Mean tumor enhancement was calculated over these selected tumor volumes and compared between tumor groups and contrast agents. Maps of differential enhancement, peak enhancement and time-to-peak were used for visual evaluation. CD31 and VEGF immunohistochemistry were performed in excised tumors. RESULTS: In the 80% least-enhancing volume, at late time points of the dynamic scan, the mean enhancement elicited by MS-325 was higher in BXPC-3 than in DU-145 tumors. In the 20% most-enhancing volume, using either contrast agents, significant difference between the two tumors types were observed only early, while at later time points of the dynamic scan the difference were obscured by the faster washout observed in the BXPC-3 tumors. Enhancement maps confirmed that BXPC-3 tumors were characterized by marked washout rate using either contrast agent, particularly in the higher enhancing peripheral rim. With MS-325 this washout pattern appeared to be specific to the BXPC-3 carcinomas, since it was not observed in the DU-145 tumors. Finally, in both tumor types, MS-325 produced significantly higher enhancement than Gd-DTPA in the late phase of the dynamic scan. Ex vivo analysis confirmed the marked presence of aberrant infiltrative stroma in BXPC-3 tumors, in which tumor vessels were embedded. In all tumors the central portion was less viable and less infiltrated by stromal tissue then the peripheral areas. CONCLUSIONS: Contrast distribution proved to be related to stromal content, which presumably produced the higher enhancement and faster washout observed in the BXPC-3 tumors. In particular, 'early' contrast-enhanced MRI, appeared as the most sensitive technique to detect the tumor portions characterized by a high stromal content, i.e. the peripheral rim of the BXPC-3 tumors. Since the same tumor models were recently investigated using FDG-PET imaging, showing inverse relationship between FDG uptake and stromal content, contrast-enhanced MRI and FDG-PET could provide complementary and comprehensive sensitivity in the assessment of carcinomas.